expect

StakingFarm Introduces a Strategic Blueprint for Crypto Staking Success Amid Market Volatility

Source Node:
Time Stamp: March 20, 2024 8:47 AM - Modified On: March 20, 2024 - Published By:
Source Cluster:
Republished By Plato

  London, England – In an era defined by the digital revolution and the emergence of cryptocurrency as a formidable asset class, StakingFarm is proud to announce its advanced approach to crypto staking, designed to navigate the tumultuous waters of market volatility. This strategic blueprint is not merely a response to the fluctuations inherent in the crypto market; it is a comprehensive guide for investors seeking to maximize their earnings through staking crypto, transforming volatility from a challenge into an opportunity. "Volatility in the crypto market is not a barrier;

PPS From Durham Unveils Highly Anticipated Album “Eriaz~” and Set to Perform Live at Coast2Coast in Atlanta

Source Node:
Time Stamp: January 29, 2024 4:27 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

Durham, NC - January 27, 2024 - Renowned hip-hop artist PPS From Durham is set to take the stage at Coast2Coast in Atlanta on January 28th, 2024, to celebrate the release of his much-anticipated album, "Eriaz~." Fans and music enthusiasts alike are eagerly awaiting this momentous occasion, as PPS From Durham gears up to deliver an electrifying performance showcasing tracks from his latest project. With "Eriaz~," PPS From Durham continues to captivate audiences with his unique blend of lyricism, storytelling, and innovative soundscapes. The album serves as a testament to

Paribus Embracing DAO transition.

Source Node:
Time Stamp: December 22, 2023 3:10 PM - Modified On: December 22, 2023 - Published By:
Source Cluster:
Republished By Plato

In our journey of developing Paribus, we’ve received a lot of feedback from our community, primarily positive and helpful. But, as is often the case when a small team controls a platform, not everyone agrees with our decisions. At every step, we’ve tried to make the best choices based on the information we had. We’ve always known that, eventually, it would be the community’s turn to take the lead in guiding Paribus. And, as we announced in our recent X-space update, that time is approaching fast with the release of

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:55 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

SydTek DAO and TCG World: Revolutionizing Education in the Metaverse with AI-Based Interactive Learning

Source Node:
Time Stamp: October 23, 2023 1:28 PM - Modified On: October 23, 2023 - Published By:
Source Cluster:
Republished By Plato

Lewes DE, October 23, 2023. SydTek DAO is on a mission to reshape the landscape of education, harnessing the power of blockchain technology and the Metaverse to make learning accessible to all. One of its most exciting partnerships is with TCG World, where it plans to establish its primary Metaverse campus. This collaboration represents a significant leap forward in bringing education to the masses within this innovative digital realm. SydTek DAO has its roots in a diverse team of educators, technologists, and blockchain enthusiasts. United by a common vision, they

The Convergence of MedTech and Blockchain: Transforming Healthcare

Source Node:
Time Stamp: September 14, 2023 4:39 PM - Modified On: September 14, 2023 - Published By:
Source Cluster:
Republished By Plato

The healthcare industry has witnessed a remarkable transformation driven by technological advancements in recent years. One groundbreaking convergence is the fusion of Medical Technology (MedTech) and blockchain technology. This synergy has the potential to revolutionize healthcare by enhancing data security, interoperability, and patient-centric care. Enhanced Data Security: One of the foremost challenges in healthcare is ensuring the security and privacy of patient data. Medical records contain sensitive information that must be protected from unauthorized access and cyber threats. Blockchain technology offers a robust solution to this problem. Blockchain operates on

Starbox Group Holdings Ltd. Announces First Half of Fiscal Year 2023 Financial Results

Source Node:
Time Stamp: August 29, 2023 11:37 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Revenue and Net Profit Increased with Technology Driven Services Revenue Accounted for Approximately 43.8% of its Revenue KUALA LUMPUR, Malaysia, August 29, 2023 / Plato / Amplifi. Starbox Group Holdings Ltd. (Nasdaq: STBX) ("Starbox" or "the Company”), a service provider of cash rebates, digital advertising, and payment solutions with a goal of becoming a comprehensive AI solutions provider within Southeast Asia, today announced its unaudited financial results for the six months ended March 31, 2023. Mr. Lee Choon Wooi, Chairman and Chief Executive Officer of Starbox, commented, “We are excited

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:20 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

SCCG Partners with Kajot Games for Distribution of iGaming Content to North America and Worldwide

Source Node:
Time Stamp: August 9, 2023 8:47 AM - Modified On: August 9, 2023 - Published By:
Source Cluster:
Republished By Plato

Las Vegas, NV – SCCG Management, a leading advisory firm in the global gambling industry, is excited to announce a strategic partnership with Kajot, for the distribution of their world-class iGaming content, with an initial focus on social gaming in the United States. The collaboration is poised to eventually expand into real-money gaming within the US market, including targeted initiatives within specific states in collaboration with tribal casinos. Stephen Crystal, Founder & CEO of SCCG, stated, “We are thrilled to join forces with Kajot, an innovative partner known for their

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating